Welcome to our dedicated page for Iovance Biotherp news (Ticker: IOVA), a resource for investors and traders seeking the latest updates and insights on Iovance Biotherp stock.
Iovance Biotherapeutics, Inc. develops and commercializes novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. Company news commonly addresses Amtagvi, described by Iovance as the first FDA-approved T cell therapy for a solid tumor indication, Proleukin, lifileucel, and pipeline work across solid tumor cancers.
Recurring updates include clinical data, regulatory disclosures, operating and financial results, corporate presentations, material agreements, and governance matters. Iovance also reports Nasdaq inducement equity grants under its Amended and Restated 2021 Inducement Plan as part of its public-company compensation disclosures.
Iovance Biotherapeutics (NASDAQ: IOVA) received conditional approval from Australia’s Therapeutic Goods Administration for Amtagvi (lifileucel) to treat adults with unresectable or metastatic melanoma after prior PD-1 and, if BRAF V600 positive, targeted therapy.
This is Amtagvi’s third marketing authorization and the first T cell therapy for a solid tumor cancer in Australia.
Iovance Biotherapeutics (NASDAQ: IOVA) received FDA clearance of its IND for IOV-5001, an IL-12 tethered tumor infiltrating lymphocyte (TIL) therapy. A Phase 1/2 basket trial starting in the second half of 2026 will assess a one-time regimen without IL-2 in multiple advanced solid tumors.
IOV-5001 is engineered to express IL-12 only within tumors and tether it to the TIL cell surface, aiming to enhance efficacy in immunologically cold tumors and improve on an earlier IL-12 TIL approach that achieved a 63% confirmed objective response rate.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options on May 21, 2026, for thirteen new non-executive employees, covering an aggregate of 93,340 shares of common stock.
The options, granted under the 2021 Inducement Plan, have a $3.70 exercise price and vest over three years with time-based milestones.
Iovance Biotherapeutics (NASDAQ: IOVA) announced that Interim CEO, President and General Counsel Fred Vogt, PhD, and Chief Financial Officer Corleen Roche will join a fireside chat at the 2026 Jefferies Global Healthcare Conference on June 4, 2026 at 1:25 p.m. ET in New York.
A live and archived webcast of the event will be accessible via the Iovance investor relations website.
Iovance (NASDAQ: IOVA) reported 1Q26 total revenue of ~$71M, about +45% YoY, with U.S. Amtagvi revenue of ~$60M and global Proleukin revenue of ~$11M. Gross margin was 41%, absorbing one-time maintenance and expansion costs. Management provided 2Q26 revenue guidance $86M–$88M and FY26 $350M–$370M. Clinical highlights include a 40% confirmed ORR in metastatic serous endometrial cancer (first five evaluable patients). Cash was approximately $319M on March 31, 2026, with operations expected to be funded into 2028.
Iovance (NASDAQ: IOVA) will report Q1 2026 financial results and provide corporate updates on Thursday, May 7, 2026 at 8:30 a.m. ET. The company will host a conference call and live audio webcast; an archived webcast will be available for one year.
Investors can register for the live or archived audio webcast via the provided registration link or access it in the Investors section at IR.Iovance.com.
Iovance (NASDAQ: IOVA) approved inducement stock options on April 16, 2026 covering 135,470 shares granted to twelve new non-executive employees under its Amended and Restated 2021 Inducement Plan. Each option has an exercise price of $3.80 (closing price on the Date of Grant) and vests over three years.
Vesting: one-third on the first anniversary of each employee’s start date, then eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) approved inducement stock options covering 3,400 shares to one new non-executive employee, granted on March 19, 2026 under the Amended and Restated 2021 Inducement Plan.
The options carry an exercise price of $3.87 (closing price on the Date of Grant) and vest over three years: one-third at the first anniversary of employment, then eight quarterly installments over the following two years, subject to continued employment.
Iovance Biotherapeutics (NASDAQ: IOVA) announced senior leadership will present at two upcoming investor conferences in March 2026. Presentations: TD Cowen 46th Annual Healthcare Conference on March 2, 2026 at 9:50 a.m. ET and Barclays 28th Annual Global Healthcare Conference fireside chat on March 11, 2026 at 9:30 a.m. ET.
Live and archived webcasts will be available via the company investor events page at the provided webcast link.
Iovance (NASDAQ: IOVA) reported positive early pilot data for lifileucel in advanced undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS), showing a 50% confirmed objective response rate (ORR) among the first six evaluable patients.
Patients were heavily pretreated (mean >2 prior lines) with mean baseline tumor burden of 117 mm. Safety was described as favorable and consistent with prior lifileucel studies. Iovance plans a single-arm registrational trial in second-line UPS and DDLPS in Q2 2026 and will engage the FDA for an accelerated approval path.